免疫检查点抑制剂联合化疗治疗晚期实体瘤综述
本综述评估免疫检查点抑制剂(ICIs)与标准化疗联合治疗晚期实体瘤的随机临床试验。联合治疗在非小细胞肺癌(NSCLC)一线及PD1/PD-L1富集肿瘤中显示总生存期和无进展生存期改善,客观缓解率优于标准化疗。未发现新的安全性信号,但序贯与同期给药的最佳模式尚待头对头比较。
要点
- ICIs联合化疗在NSCLC一线及PD1/PD-L1富集肿瘤中显示生存获益。
- 联合治疗未发现新的安全性信号。
- 序贯与同期 chemoimmunotherapy 的最佳模式尚无头对头比较。
核心结论
- ICIs与化疗联合在晚期实体瘤中显示协同效应,尤其在NSCLC一线和PD1/PD-L1富集肿瘤中改善总生存期和客观缓解率。
- 抗PD-L1 avelumab维持治疗膀胱癌的生存改善提示序贯与同期给药模式需进一步比较。
- 目前无头对头试验比较同期 chemoimmunotherapy 与化疗减瘤后序贯ICIs。
研究设计与样本
- 综述评估ICIs与化疗同期给药的随机临床试验,以评估晚期实体瘤的临床疗效和安全性。
主要发现
- 联合治疗在NSCLC一线及PD1/PD-L1富集肿瘤中显示总生存期改善和客观缓解率优于标准化疗。
- avelumab维持治疗膀胱癌显示生存改善。
- 未发现新的安全性信号。
- 头颈癌或NSCLC一线帕博利珠单抗联合化疗后显示PFS2改善。
临床怎么用
- 在NSCLC一线和PD1/PD-L1富集肿瘤中可考虑ICIs联合化疗。
- 膀胱癌中avelumab维持治疗可作为序贯策略选项。
局限性
- 缺乏头对头试验比较同期 chemoimmunotherapy 与化疗后序贯ICIs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of immune checkpoint inhibitors (ICIs), especially anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), has changed practices in oncology, becoming a new standard of care in first or subsequent lines for several cancer subtypes. Recent data have highlighted the ability of standard chemotherapy to enhance immunogenicity and/or to break immunoresistance of the tumour and its microenvironment, leading to a rationale for the use of ICIs in combination with the standard chemotherapy regimen to improve efficacy of cancer treatment. Here, we propose to review randomised clinical trials evaluating concomitant administration of ICIs and chemotherapy, to assess clinical efficacy and safety profiles in advanced solid tumours. Association of these two modes of action on treatments has shown improved overall survival and better objective response rates than standard chemotherapy, especially in first-line treatment of non-small cell lung cancer (NSCLC) and for PD1/PD-L1 enriched tumours, highlighting a potential synergistic effect of this treatment combination in certain tumour types. However, improved survival results with the use of anti-PD-L1 avelumab as a maintenance schedule for bladder cancer raises the question of the most appropriate approach between sequential and concomitant administration of chemoimmunotherapy. To date, no trials have compared in a head-to-head protocol the administration of concomitant chemoimmunotherapy with chemotherapy, used for tumour debulking, followed by administration of ICIs. Regarding the tolerance profile, no new safety signals were found with the combination tested to date. Interestingly, recent results have shown an improved Progression Free survival 2 (PFS2) (defined as the progression after the next line of therapy) in head-and-neck cancers or NSCLC after a first-line pembrolizumab-chemotherapy combination, suggesting a potential long-lasting effect of ICIs when used in combination in the first-line setting.
引用
- Larroquette M, Domblides C, Lefort F, et al. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. Eur J Cancer. 2021. PMID: 34655837. doi:10.1016/j.ejca.2021.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。